secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266860
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q3 net loss $26.9M; positive ADI-001 Phase 1 data in LN/SLE; cash runway extended to H2 2027
--------------------------------------------------------------------------------

- Positive Phase 1 ADI-001 data in 7 LN/SLE patients: SLEDAI-2K reductions, improved renal function, no Grade 2+ CRS or ICANS.
- Plans FDA meeting Q1 2026 for potentially pivotal trial; initiation targeted Q2 2026.
- Q3 2025 net loss $26.9M ($0.29 loss per share); R&D $22.9M, G&A $5.1M; cash $103.1M as of Sep 30.
- Raised $74.8M net proceeds in October 2025 registered direct offering; cash runway into H2 2027.
- ADI-212 regulatory filing for mCRPC on track Q1 2026; initial data expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000119312525266860/0001193125-25-266860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000119312525266860/acet-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer